

Self-Management in Allergic Rhinitis: Strategies, Outcomes and Integration into Clinical Care

Giorgio Ciprandi 

Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy

Correspondence: Giorgio Ciprandi, Allergy Clinic, Casa di Cura Villa Montallegro, Via Boselli 5, Genoa, 16146, Italy, Tel +39 3483200821, Email gio.cip@libero.it

Abstract: Allergic rhinitis (AR) is a common disease, characterized by typical symptoms and type 2 inflammation. Standard treatment is usually effective and safe, and most medications are available as over-the-counter (OTC). Therefore, AR patients, mostly at the AR onset or if symptoms are mild, prefer to manage symptoms themselves. However, self-management could be associated with problems, including inadequate control or medication abuse. Therefore, this paper aimed at presenting and discussing this issue. Ideally, self-management should be conducted under medical supervision. In this regard, telemedicine could represent a valuable tool for implementing self-management. Visual analog scale (VAS) is a perfect parameter to measure symptom severity, medications use, and AR control. In addition, VAS is easily monitored over time. Presently, a mobile application allows to AR patients of self-managing themselves. Therefore, mobile healthcare may supply fundamental support in communication and decision-making. In this regard, VAS represents the best tool to monitor symptoms' severity and control over time. Finally, pharmacological and non-pharmacological remedies are numerous and effective but should be used wisely.

Keywords: allergic rhinitis, self-management, mobile healthcare, visual analog scale, symptoms

Introduction

Allergic rhinitis (AR) is a nasal disease driven by type 2 inflammation.¹ Type 2 inflammation accounts for symptoms, including itching, sneezing, watery rhinorrhea, and congestion.² In particular, nasal obstruction reflects the underlying type 2 inflammation and is the key symptom of hay fever.³ However, AR symptoms typically and quickly accomplish the exposure to inhalant allergens.⁴

Allergic rhinitis is a relevant medical condition as it is prevalent, accounts for a significant burden, and affects the quality of life. Namely, some countries have an AR prevalence of up to 50%.⁵ The socio-economic cost is substantial, as it may arrive at 50 billion/year in the European Union.⁶ Moreover, even if AR is not a severe disease, the quality of life is profoundly impaired.⁷

The most relevant allergens causing AR include pollens (ie, grass, tree, and weed), indoor allergens (ie, house dust mites and pets), and molds; their presence and distribution depend on geography and climate.⁸

Two main classifications categorize AR: the old classification considers the seasonal and perennial AR (based on symptom duration), the recent classification, recommended by the Allergic Rhinitis and Impact on Asthma (ARIA) guidelines, includes intermittent and persistent also considering symptom severity, eg, mild or moderate/severe.⁹

There is extensive evidence that AR is commonly associated with other allergic diseases, mainly conjunctivitis and asthma.¹⁰ Notably, this multimorbidity, associated with the common polysensitization, significantly affects the severity of allergic rhinitis.^{11,12}

The diagnosis of AR is based on a detailed history, testing for allergen-specific IgE, and consistency.¹³ In addition, the severity of type 2 inflammation could be detected and monitored by investigating eosinophils in the mucosa or blood.¹⁴

The treatments for AR include patient education and engagement, allergen avoidance, drugs, non-pharmacological remedies, allergen immunotherapy, and, in selected patients, surgery.¹⁵ First, however, it has to be underlined that antiallergic

medications are usually adequate. Still, the adherence rate is poor, meaning closer patient involvement is indispensable, as will be analyzed below.

Education is the first cornerstone of AR management and is fundamental to achieving optimal patient engagement that can assure perfect adherence to prescribed and shared strategies.¹⁶

Allergen avoidance could be ideal for allergic patients, as any symptom may arise without allergen exposure. Unfortunately, except in a few cases, it is almost always an impassable road because exposure is practically inevitable for most allergens.¹⁷

Concerning pharmacological options, oral and intranasal antihistamines, intranasal corticosteroids, and fixed combination intranasal antihistamines and corticosteroids represent the first-line treatments.^{15–18} The outcomes on practical aspects of AR management were derived from the GRADE-based guidelines and real-world studies.¹⁹ In particular, real-life studies reported that patients prefer oral medications, combined intranasal corticosteroids and antihistamines are potent treatments that act between 10 and 60 minutes, and patients prefer symptomatic (on-demand) treatment to a continuous schedule.⁴

Non-pharmacological remedies include nasal lavage with saline solutions (isotonic or hypertonic), nutraceuticals, probiotics, and natural compounds.²⁰

Allergen immunotherapy (AIT) is presently the only treatment that targets the cause of AR as it is allergen-specific, modifies the natural course, has long-lasting effects, dampens type 2 inflammation, and restores a physiological T regulatory function.¹³ However, AIT is expensive, requires long periods of administration (at least three years), adverse reactions (even if usually local, mild, and self-resolving) are frequent, mainly for sublingual routes, and adherence is poor.²¹

As a result, AR patients are sometimes disoriented and prefer to manage their illness independently from the doctor. This attitude should require particular attention and a rethinking of the approach to AR. Indeed, the treatment for patients with AR should be personalized considering the phenotype, including symptom duration and severity, endotype, comorbidities, concomitant therapies, and personal preference.⁴ In this regard, mobile technology and telemedicine may significantly improve the quality of care. Moreover, the COVID-19 pandemic further underscored the need to implement the traditional vision of medicine with new approaches based on a patient-center point of view. Consistently, self-management could significantly affect outcomes and adherence to treatments.

Strategies in Self-Management

Self-management of allergic rhinitis represents an actual modality of approaching this disease, bypassing real doctor's visits. Of course, self-management may present relevant biases, including inadequate disease control and inappropriate prescriptions. However, self-management may be performed in different ways: directly by patients independently acting, asking advice from relatives/friends, or interacting with healthcare providers (physicians, pharmacists, nurses). Some researchers investigated this issue in different settings.

Self-Management of Allergic Rhinitis: The Evidence in Pharmacy

Evidence shows that self-care and self-management may significantly improve adherence and reduce the disease burden.^{22,23} In this regard, the World Health Organization (WHO) defined self-care as “activities that individuals, families, and communities undertake intending to enhance health, prevent disease, limit illness, and restore health”.²⁴

Medication knowledge and adherence are important characteristics of self-management, particularly understanding when and how to utilize prescription and over-the-counter (OTC) medicines.²² Moreover, the availability of many drugs as OTC or without the need for a prescription, the non-reimbursement of many medications, and non-pharmacological remedies have reduced the recourse to doctors, saving time and costs. On the other hand, there is a growing awareness among primary care doctors, pharmacists, healthcare workers, and patients (and their relatives) that appropriate, cost-effective, and safe treatment is crucial to control AR.²⁵ Alike, self-management, including self-monitoring, reduces the need for follow-up visits.²² In this scenario, the role of pharmacists is relevant in supporting AR patients.²⁶ In this regard, several studies investigated the role of pharmacists in AR self-management.

Kuehl et al surveyed 146 US patients with AR.²² The survey used an online questionnaire including 13 practical questions. The primary outcomes consisted of assessing the use of medications for AR, prescribed or not by doctors, and interactions with doctors or pharmacists about them. The results showed that 53% of AR patients used both prescribed

drugs and OTCs (self-managed). In addition, most of these subjects (53%) discussed with their doctors the use and indications of the prescribed medications for AR. Usually, these subjects are repeatedly discussed with doctors about the prescriptions. However, refill prescriptions frequently (75%) occurred without a doctor visit. In addition, two-thirds of patients discussed non-prescription drugs with pharmacists. As a result, the authors concluded that most interactions occurred with pharmacists instead of doctors.

Carr and Yawn reviewed the primary care management of patients with AR considering using OTC drugs.²⁷ Namely, as several medications for AR are available as OTC, most patients (about two-thirds) self-manage before consulting a doctor. It depends on the perception that AR is not a severe disease. However, this review underlined that most patients believe that AR significantly affects the quality of life more than perceived symptoms. As a result, AR requires patients to be treated.

Moreover, although self-management could be effective, many AR patients prefer an interview with a doctor. Indeed, as several pharmacological classes are available, including antihistamines, decongestants, and nasal corticosteroids, several patients are confused. In addition, this review underscored that most patients do not know the effectiveness of intranasal corticosteroids but believe that these medications are unsafe. Therefore, the authors concluded that communication with AR patients should improve, involving healthcare providers in addition to doctors, also concerning the use of delivery devices for intranasal administration.²⁷

Tan et al investigated the AR burden in an Australian community pharmacy and the possible opportunities for specific interventions.²⁸ The study used a questionnaire administered to the customers purchasing nasal treatments. The study included 296 participants: 70% self-managed AR using OTCs, and only 44% had a doctor's diagnosis of AR. Interestingly, the most common symptom was nasal congestion, and the most used drug was antihistamines. This finding suggested a suboptimal AR treatment as nasal congestion responds better to nasal corticosteroids.²⁹

Moreover, one-third of subjects had persistent moderate-severe symptoms with a relevant impact on daily activities. Lastly, the drug choice usually was based on the subjective perception of drug efficacy. Therefore, the authors concluded that many patients were undertreated and needed a doctor visit.

Another Australian study investigated the possible factors influencing AR patients' choices in self-management.³⁰ The study analyzed the data of 41 AR patients. Quality of life was perceived as significantly impaired. The most critical factors driving AR management were: the general practitioners, pharmacists, and personal experience. However, the study demonstrated that many factors could influence the patient's decisions, but the role of healthcare providers (ie, doctors and pharmacists) remained relevant.

The same Australian group conducted a cross-sectional study in some community pharmacies of Sydney.³¹ The study compared patients self-selecting medications and patients consulting a pharmacist. The study recruited 202 AR patients; 65% had a doctor's AR diagnosis and 70% self-selected drugs. These last subjects had moderate-severe symptoms most frequently, such as four times higher odds, and perceived low impact on their quality of life. The authors concluded that pharmacists should engage self-managing patients to discuss AR management.

A retrospective study in Singapore evaluated a community pharmacist-led AR management service based on patient assessment, personalized recommendations, and follow-up.³²

The study included 45 customers, and 32 received at least one follow-up. At baseline, pharmacists recommended primarily oral antihistamines (33%), topical corticosteroids (29%), and non-pharmacological remedies (28%). The study highlighted that customers appreciated the role of pharmacists, but there needed to be more protected time and interest from customers.

Self-Management of Allergic Rhinitis in Primary Care

South-East Asian researchers considered the impact of the COVID-19 pandemic on AR management in primary care.³³ Namely, the COVID-19 pandemic significantly affected the healthcare system. It provided the opportunity to implement self-care and self-management due to the lockdown and reduced availability of healthcare resources. In addition, COVID-19 represented the ideal opportunity to use digital technology in Medicine, such as telemedicine. It is well known that limited access to physical visits promoted self-care strategies, including self-diagnosis, OTCs use, and

complementary therapies.³³ However, telemedicine allows real-time synchronous interaction between patients and healthcare providers that have been recognized to be an essential part of clinical practice by many doctors.³⁴

Moreover, telemedicine consistently receives high patient satisfaction from allergic subjects.^{35,36} In this regard, the MASK (Mobile Airways Sentinel Network) app is highly ranked by European and Asian AR patients, as reported further. Indeed, the MASK app is easily accessible, user-friendly, and compatible with AR self-management.³⁴ Moreover, the MASK app may be considered a system engaging, highly intuitive, and appealing.³⁷ In this regard, the benefits of mobile technology include the possibility of self-monitoring using an electronic diary, personalized feedback, and individual education on ideal approaches.³³ These aspects can implement self-management and adherence to treatments.³⁸

Therefore, AR management in the real world is based on self-management, including continuous follow-up on symptom monitoring, education, allergen avoidance, and treatment adherence.³³ The self-management desirably entails a dynamic interaction with GPs.³⁹

Usually, patients refer to their GPs when symptoms are acute, affect the quality of life, and self-medication (mainly OTCs) is ineffective.⁴⁰ In this setting, the definition of the patient profile allows the identification of the appropriate treatment.⁴⁰ However, primary care doctors need to be made aware of the importance of AR guidelines.⁴¹ However, guidelines do not always reflect patients' real needs and real-life experiences.⁸ As a result, there is a need to implement primary care awareness of the relevance of AR and its management and ensure close contact with patients using telemedicine in primary care practice.

Self-Management of Allergic Rhinitis Using a Designated App

The mobile airways sentinel network (MASK) app represents an information and communication technology system based on the patient; this application is available in the majority of European countries.^{42–44} The application contains a list of all medications that have been adapted to each country and a colored visual analog scale to measure the AR control and treatment response. In addition, MASK is scaled by the EU European Innovation Partnership on Active and Healthy Ageing strategy with support from EU grants and the World Health Organization.^{44,45} The MASK app allows daily monitor symptoms, also concerning the individual variability if present comorbidity. Indeed, AR patients with comorbidities present more severe symptoms.^{46–48} Notably, ocular symptoms were most common in polysensitized patients.

Moreover, it has to be underlined that the MASK app (available on the web as MASK-air[®]) constitutes a Good Practice of digitally-enabled Health and digitally-enabled, integrated, person-centered care for patients with allergic rhinitis.^{49,50}

Outcomes for Self-Management

In the era of patient-reported outcomes measures (PROMs), the subjective assessment of symptoms represents a mainstay in the present concept of patient-centered management, as recently outlined.^{51–54} As a consequence, PROMs are also very fruitful in self-management.

Different measures have been proposed as PROMs in allergic rhinitis, including total and single symptom scores, visual analog scale (VAS), quality of life, and several questionnaires. However, only VAS seems suitable for AR self-management as patients can easily use it. Indeed, the other measures need the support of healthcare providers or questionnaire forms, which are unavailable at home.

VAS is a psychometric test considering the subjective (patient) perception of symptom severity. Historically, VAS was initially used to measure pain intensity, mainly in the emergency room setting.^{55,56} However, VAS has been extensively used successively in patients with allergic rhinitis.⁵⁷ More than 500 studies have been performed using VAS in allergic rhinitis. The reasons for this popularity depend on its ease of being understood and executed, simplicity, clarity, and rapid compilation. Moreover, it may be used everywhere and anytime.

In particular, VAS of nasal obstruction perception is well correlated with objective measurement by rhinomanometry.⁵⁸ Also, VAS may identify an AR patient candidate for spirometry,⁵⁹ suggest a response to decongestion test in adults and adolescents,^{60,61} and measures the use and effectiveness of treatments.^{10,62,63} However, the best use of VAS in allergic rhinitis has been developed by the MASK project.

MASK-Air[®] App

The MASK-air[®] was designed to implement AIRWAYS-ICPs.⁵¹ Furthermore, MASK-air[®] consists of a patient-centered app; it presently is available in 27 countries and 19 languages with around 35,000 users.⁶⁴ This intensive use made it possible to acquire much information on AR patients. In particular, there is evidence that AR patients are poorly adherent to treatment;⁶⁵ most patients use self-medications,⁶⁶ on-demand treatments,⁶⁷ and switch therapies.⁶⁸ Interestingly, MASK-air[®] use showed us that most patients do not accomplish doctors' prescriptions,^{65,69} and oral antihistamines are the most used medications and inappropriately dispensed in the pharmacy.⁷⁰ Moreover, AR control is well correlated with medication use, such as when AR was uncontrolled, an increased number of drugs was taken.⁶⁶

Consequently, the MASK-air[®] studies provided relevant, helpful information to modify the actual approach in managing AR, mainly concerning the relationship between patient and healthcare provider. In this context, considering and monitoring AR control is the cornerstone of AR management. Consistently, VAS allows us to measure the AR control grade as values < 5 expressed poor control.⁷¹ However, the cut-off values have been re-identified, so defining complete AR control (VAS = 0), good control (VAS = 1–20), partial control (VAS = 21–35), and poor control (VAS > 35) as recently reported.⁷² Also, there is evidence that changes in VAS, recorded by this app, may have altered treatment and other outcomes.⁷³

In conclusion, digital support in managing AR patients is clinically relevant and supports self-management under medical supervision.

Integration into Clinical Care

As previously discussed, AR self-management represents a whole way of care in the real world. However, different scenarios may occur. Usually, at the onset of allergic rhinitis, the patient self-manages using preferably non-pharmacological remedies or OTCs or medications suggested by relatives/friends. If symptoms are moderate/severe, patients commonly take advice from pharmacists or report to primary care doctors. Secondly, if AR is uncontrolled, primary care doctors or patients consult a specialist (an allergist or a rhinologist). However, most patients continue to autonomously self-manage themselves or, under medical supervision, self-manage.

Self-management is possible thanks to the availability of effective remedies and, preferably, also using mobile technology. In addition, there is awareness from physicians that education and communication are basilar requirements to manage AR.⁷⁴ However, adequate self-management requires adequate literacy by patients.^{75,76} Namely, appropriate self-medication requires adequate knowledge of the indications for various treatments, which is rarely the case in reality.

On the other hand, the remedies for AR are extremely numerous, and it may be disorienting patient choice. Therefore, classically, remedies may be classified as pharmacological and non-pharmacological.

Non-pharmacological remedies include nasal saline lavage (using isotonic or hypertonic solutions), natural products, and avoidance measures.⁷⁷ In particular, nasal lavage is particularly fruitful as it removes allergens, inflammatory mediators, and excessive secretions using isotonic solutions.⁷⁸ Hypertonic saline solutions also medicate the nasal cavity as they exert anti-inflammatory and decongestant activities.⁷⁹ In addition, a list of natural products has been recently provided, mainly considering the evidence level of studies.²⁰

Pharmacological treatments mainly include antihistamines (both oral and intranasal) and topical corticosteroids. Most antihistamines are available as OTC or may be dispensed without a medical prescription.⁸⁰ However, most belong to the first generation, such as sedative antihistamines. Thus, they should be highly discouraged. Intranasal corticosteroids are freely available for purchase only in certain countries (eg, the US), whereas, in the European Union, they need a medical prescription. However, the Italian Agency for Drugs permitted the use without a prescription for beclomethasone nasal spray.

It is, therefore, evident that use of mobile health apps to capture data may be helpful in management. However, whether use of mobile applications actually affect AR outcomes is not proven, and primary care physicians, and even busy pharmacists, may question the amount of time spend by them to review relatively small changes in VAS and respond to them real time.

Additional Techniques in Self-Management

Patients wishing to self-manage can obtain important information from several apps that provide useful guidance. Several apps provide pollen count data so that patients may avoid excessive pollen exposure, mainly concerning outdoor

activities. Of course, patients should find data concerning the precise geographic area and information should be reliable. In addition, meteo apps may give interesting information about the weather data, mainly concerning temperature, humidity, and overall wind (these variables significantly affect pollen scattering).

Also, apps providing air quality are useful for AR patients as they indicate the air concentration of pollutants that, if elevated, worsen AR symptoms.

Self-management can also benefit from the use of various tools that improve the condition of the home environment, such as HEPA filters, dehumidifiers, air conditioners and suitable window frames. These devices may be fruitful in reducing allergen exposure.

However, self-management can be remarkably effective when combined with telemedicine. In fact, the possibility to quickly seek medical advice and/or have medical supervision on self-management allows for an optimal strategy. In this regard, MASK-air[®] could represent a suitable example.

Conclusive Remarks

Self-management of allergic rhinitis represents a realistic approach to caring for this disease, as many patients actually manage their condition independently. Self-management may be a suitable option in the global healthcare scenario as it may save costs and time. However, there is evidence that optimal self-management requires adequate literacy and interaction with physicians and best specialists. Mobile healthcare may supply fundamental support in communication and decision-making. In this regard, VAS represents the best tool to monitor symptoms' severity and control over time. Also, pharmacological and non-pharmacological remedies are numerous and effective but should be used wisely. In conclusion, apps to manage AR symptoms may be very useful for patients, but since this appears to be a newer way to approach self-management they should be combined with clinical care.

Disclosure

The author reports no conflicts of interest in this work.

References

- Blöndal V, Sundbom F, Zhou X, et al. Allergic sensitisation and type-2 inflammation is associated with new-onset and persistent allergic disease. *Clin Transl Allergy*. 2023;13(4):e12240. doi:10.1002/ct2.12240
- Ciprandi G, Tosca MA. Turbinate hypertrophy, allergic rhinitis, and otitis media. *Curr Allergy Asthma Rep*. 2021;21(9):44. doi:10.1007/s11882-021-01021-y
- Ciprandi G, Cirillo C, Klersy C, Marseglia GL, Caimmi D, Vizzaccaro A. Nasal obstruction is the key symptom in hay fever patients. *Otolaryngol Head Neck Surg*. 2005;133(3):429–435. doi:10.1016/j.otohns.2005.05.049
- Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. *Nature Rev*. 2020;6:95.
- Wheatley LM, Togias A, Solomon CG. Allergic rhinitis. *N Engl J Med*. 2015;372(5):456–463. doi:10.1056/NEJMc1412282
- Colas C, Brosa M, Anton E, et al. Estimate of the total costs of allergic rhinitis in specialized care based on real- world data: the FERIN study. *Allergy*. 2017;72(6):959–966. doi:10.1111/all.13099
- Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. *Immunol Allergy Clin North Am*. 2016;36(2):235–248. doi:10.1016/j.iac.2015.12.002
- Zhang Y, Lan F, Zhang L. Advances and highlights in allergic rhinitis. *Allergy*. 2021;76(11):3383–3389. doi:10.1111/all.15044
- Brožek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. *J Allergy Clin Immunol*. 2017;140(4):950–958. doi:10.1016/j.jaci.2017.03.050
- Tosca MA, Licari A, Pistorio A, Marseglia GL, Ciprandi G, Marseglia GL; “Control’Asma” Study Group. Control’Asma Project: new insights. *Pediatr Allergy Immunol*. 2020;31(Suppl 26):23–25. doi:10.1111/pai.13353
- Anto JM, Bousquet J, Akdis M, et al. Mechanisms of the Development of Allergy (MeDALL): introducing novel concepts in allergy phenotypes. *J Allergy Clin Immunol*. 2017;139(2):388–399. doi:10.1016/j.jaci.2016.12.940
- Ciprandi G, Cirillo I. Monosensitization and polysensitization in allergic rhinitis. *Eur J Intern Med*. 2011;22(6):e75–e79. doi:10.1016/j.ejim.2011.05.009
- Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. *Allergy*. 2018;73(4):765–798. doi:10.1111/all.13317
- Ciprandi G, Varricchio A, Tajana G, La Mantia I, Tommasino C. Peripheral eosinophil counts correlate with nasal eosinophil counts in patients with rhinitis. *J Investig Allergol Clin Immunol*. 2018;28(6):428–430. doi:10.18176/jiaci.0306
- Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). *Clin Exp Allergy*. 2017;47(7):856–889. doi:10.1111/cea.12953
- Bousquet JJ, Schünemann HJ, Togias A, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. *Clin Transl Allergy*. 2019;9(1):44. doi:10.1186/s13601-019-0279-2

17. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: allergic rhinitis - 2023. *Int Forum Allergy Rhinol.* 2023;13(4):293–859.
18. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. *J Allergy Clin Immunol.* 2020;146(4):721–767. doi:10.1016/j.jaci.2020.07.007
19. Bousquet J, Anto JM, Bachert C, et al. From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. *Eur Resp J.* 2019;54(6):1901023. doi:10.1183/13993003.01023-2019
20. Ciprandi G, Tosca MA. Nutraceuticals and non-pharmacological remedies for managing patients with allergic rhinitis. *Minerva Pediatr.* In press 2023.
21. Nelson HS. Future directions in allergen immunotherapy. *Allergy Asthma Proc.* 2022;43(4):356–362. doi:10.2500/aap.2022.43.210098
22. Kuehl BL, Abdunour S, O'Dell M, Kyle TK. Understanding the role of the healthcare professional in patient self-management of allergic rhinitis. *SAGE Open Med.* 2015;3:2050312115595822. doi:10.1177/2050312115595822
23. Chodosh J, Morton SC, Mojica W. Meta-analysis: chronic disease self-management programs for older adults. *Ann Intern Med.* 2005;143(6):427–438. doi:10.7326/0003-4819-143-6-200509200-00007
24. World Health Organization (WHO). *Global Status Report on Noncommunicable Diseases 2010.* Geneva: World Health Organization; 2011.
25. Smith M, Bates DW, Bodenheimer T, Cleary PD. Why pharmacists belong in the medical home. *Health Aff.* 2010;29(5):906–913. doi:10.1377/hlthaff.2010.0209
26. You JH, Wong FY, Chan FW, Wong EL, Yeoh E-K. Public perception on the role of community pharmacists in self-medication and self-care in Hong Kong. *BMC Clin Pharmacol.* 2011;11(1):19. doi:10.1186/1472-6904-11-19
27. Carr WW, Yawn BP. Management of allergic rhinitis in the era of effective over-the-counter treatments. *Postgrad Med.* 2017;129(6):572–580. doi:10.1080/00325481.2017.1333384
28. Tan R, Cvetkovski B, Kritikos V, et al. Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. *Asthma Res Pract.* 2017;3(1):8. doi:10.1186/s40733-017-0036-z
29. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. *Int Arch Allergy Immunol.* 2004;134(1):34–40. doi:10.1159/000077531
30. Cvetkovski B, Tan R, Kritikos V, et al. A patient-centric analysis to identify key influences in allergic rhinitis management. *Prim Care Resp Med.* 2018;28(1):34. doi:10.1038/s41533-018-0100-z
31. Tan R, Cvetkovski B, Kritikos V, et al. Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection. *Pharm Pract.* 2018;16:1332.
32. Ying Yap JS, Qiag Tang CW, Ling Hor HM, Ka Chong JB, Yap KZ. Process evaluation of the Community Pharmacist-Led Allergic Rhinitis Management (C-PhARM) service in Singapore. *Pharmacy.* 2019;7(2):56. doi:10.3390/pharmacy7020056
33. Abdullah B, Snidvongs K, Lestari Poerbonegoro N, Sutikno B. Reshaping the management of allergic rhinitis in primary care: lessons from the COVID-19 pandemic. *Int J Environ Res Pub Health.* 2022;19(20):13632. doi:10.3390/ijerph192013632
34. Thong HK, Wong DKC, Gendeh HS, Saim L, Athar PP, Saim A. Perception of telemedicine among medical practitioners in Malaysia during COVID-19. *J Med Life.* 2021;14(4):468–480. doi:10.25122/jml-2020-0119
35. Thomas I, Siew L, Rutkowski K. Synchronous telemedicine in allergy: lessons learned and transformation of care during the COVID-19 pandemic. *J Allergy Clin Immunol Pract.* 2021;9(1):170–176.e1. doi:10.1016/j.jaip.2020.10.013
36. Waibel KH, Bickel RA, Brown T. Outcomes from a regional synchronous tele-allergy service. *J Allergy Clin Immunol Pract.* 2019;7(3):1017–1021. doi:10.1016/j.jaip.2018.10.026
37. Tan R, Cvetkovski B, Kritikos R, et al. Identifying an effective mobile health application for the self-management of allergic rhinitis and asthma in Australia. *J Asthma.* 2019;57:1–15.
38. Thakkar J, Kurup R, Laba TL, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. *JAMA Intern Med.* 2016;176(3):340–349. doi:10.1001/jamainternmed.2015.7667
39. Huang X, Matricardi PM. Allergy and asthma care in the mobile phone era. *Clin Rev Allergy Immunol.* 2019;56(2):161–173. doi:10.1007/s12016-016-8542-y
40. Baharudin A, Latiff AH, Yap F, et al. Using patient profiles to guide the choice of antihistamines in the primary care setting in Malaysia: expert consensus and recommendations. *Clin Risk Manag.* 2019;15:1267–1275. doi:10.2147/TCRM.S221059
41. Abdullah B, Snidvongs K, Recto M, Poerbonegoro NL, Wang DY. Primary care management of allergic rhinitis: a cross-sectional study in four ASEAN countries. *Multidiscip Respir Med.* 2020;16:726.
42. Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin Transl Allergy.* 2016;6(4):47. doi:10.1186/s13601-016-0137-4
43. Bourret R, Bousquet J, Mercier J, et al. MASK rhinitis, a single tool for integrated care pathways in allergic rhinitis. *World Hosp Health Serv.* 2015;51(3):36–39.
44. Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel Network for Allergic Rhinitis (MASK-Rhinitis): the new generation guideline implementation. *Allergy.* 2015;70(11):1372–1392. doi:10.1111/all.12686
45. Bousquet J, Farrell J, Crooks G, et al. Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (Action Plan B3: area 5). *Clin Transl Allergy.* 2016;6(1):29. doi:10.1186/s13601-016-0116-9
46. Bousquet J, Mohammad Y, Bedbrook A, et al. Country activities of Global Alliance against Chronic Respiratory Diseases (GARD): focus presentations at the 11th GARD General Meeting, Brussels. *J Thorac Dis.* 2018;10(12):7064–7072. doi:10.21037/jtd.2018.12.84
47. Siroux V, Boudier A, Nadif R, Lupinek C, Valenta R, Bousquet J. Association between asthma, rhinitis, and conjunctivitis multimorbidities with molecular IgE sensitization in adults. *Allergy.* 2019;74(4):824–827. doi:10.1111/all.13676
48. Amaral R, Bousquet J, Pereira AM, et al. Disentangling the heterogeneity of allergic respiratory diseases by latent class analysis reveals novel phenotypes. *Allergy.* 2018;74(4):698–708. doi:10.1111/all.13670
49. Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. *Clin Transl Allergy.* 2019;9(1):16. doi:10.1186/s13601-019-0252-0
50. Bousquet J, Farrell J, Illario M. Aligning the good practice MASK with the objectives of the European innovation partnership on active and healthy ageing. *Allergy Asthma Immunol Res.* 2020;12(2):238–258. doi:10.4168/aaair.2020.12.2.238

51. Bousquet J, Addis A, Adcock I, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). *Eur Respir J*. 2014;44(2):304–323. doi:10.1183/09031936.00014614
52. Li AR, Zhang K, Reddy PD, et al. Systematic review of measures of disease severity in rhinitis. *Int Forum Allergy Rhinol*. 2021;11(9):1367–1377. doi:10.1002/alr.22794
53. Vieira RJ, Sousa-Pinto B, Cardoso-Fernandes A, et al. Control of Allergic Rhinitis and Asthma Test: a systematic review of measurement properties and COSMIN analysis. *Clin Transl Allergy*. 2022;12(9):e12194. doi:10.1002/ct2.12194
54. Pedersen CK, Haase C, Aanaes K, von Buchwald C, Backer V. An update on patient reported outcomes in type 2 inflammation airway disease. *Curr Opin Allergy Clin Immunol*. 2023;23(1):1–8. doi:10.1097/ACI.0000000000000873
55. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res*. 2011;63(Suppl 1):S240–S252. doi:10.1002/acr.20543
56. Karcioğlu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the pain scales in adults: which to use? *Am J Emerg Med*. 2018;36(4):707–714. doi:10.1016/j.ajem.2018.01.008
57. Sousa-Pinto B, Azevedo LF, Jutel M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. *Allergy*. 2022;77(7):2147–2162. doi:10.1111/all.15199
58. Ciprandi G, Mora F, Cassano M, Gallina AM, Mora R. Visual analog scale (VAS) and nasal obstruction in persistent allergic rhinitis. *Otolaryngol Head Neck Surg*. 2009;141(4):527–529. doi:10.1016/j.otohns.2009.06.083
59. Ciprandi G, Tosca MA, Signori A, Cirillo I. Visual analogue scale assessment of nasal obstruction might define patients candidates to spirometry. *Rhinology*. 2011;49(3):292–296. doi:10.4193/Rhino10.303
60. Ciprandi G, Klersy C, Ameli F, Cirillo I. Clinical assessment of a nasal decongestion test by visual analog scale in allergic rhinitis. *Am J Rhinol*. 2008;22(5):502–505. doi:10.2500/ajr.2008.22.3214
61. Marseglia GL, Cirillo I, Klersy C, et al. Clinical assessment of nasal decongestion test by VAS in adolescents. *Pediatr Allergy Immunol*. 2009;20(2):187–191. doi:10.1111/j.1399-3038.2008.00750.x
62. Ciprandi G, La Mantia I. VAS for assessing the perception of antihistamines use in allergic rhinitis. *Acta Biomed*. 2019;90(7–S):41–44. doi:10.23750/abm.v90i7-S.8657
63. Zhang K, Li AR, Miglani A, Nguyen SA, Schlosser RJ. Effect of medical therapy in allergic rhinitis: a systematic review and meta-analysis. *Am J Rhinol Allergy*. 2022;36(2):269–280. doi:10.1177/19458924211041438
64. Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. *Clin Transl Allergy*. 2018;8(1):45. doi:10.1186/s13601-018-0227-6
65. Menditto E, Costa E, Midao L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. *Clin Exp Allergy*. 2019;49(4):442–460. doi:10.1111/cea.13333
66. Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights on control and treatment of allergic rhinitis. The MASK study. *J Allergy Clin Immunol*. 2019;144(1):135–143.e6. doi:10.1016/j.jaci.2019.01.053
67. Sousa-Pinto B, Sa-Sousa A, Vieira RJ, et al. Behavioural patterns in allergic rhinitis medication in Europe: a study using MASK-air(R) real-world data. *Allergy*. 2022;77(9):2699–2711. doi:10.1111/all.15275
68. Vandenas O, Suarathana E, Riffart C, Lemiere C, Le Moual N, Bousquet J. The impact of work-related rhinitis on quality of life and work productivity: a General Workforce-Based Survey. *J Allergy Clin Immunol Pract*. 2020;8(5):1583–1591.e5. doi:10.1016/j.jaip.2019.12.033
69. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. *Allergy*. 2018;73(9):1763–1774. doi:10.1111/all.13406
70. Bousquet J, Schroder-Bernhardi D, Bachert C, et al. Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. *Clin Exp Allergy*. 2021;51(8):1033–1045. doi:10.1111/cea.13884
71. Bedard A, Basagana X, Anto JM, et al. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. *Clin Transl Allergy*. 2020;10(1):62. doi:10.1186/s13601-020-00342-x
72. Sousa-Pinto B, Sa-Sousa A, Vieira RJ, et al. Cutoff values of MASK-air patient-reported outcome measures. *J Allergy Clin Immunol Pract*. 2023;11(4):1281–1289. doi:10.1016/j.jaip.2022.12.005
73. Mitsias DI, Dimou MV, Lakoumentas J, et al. Effect of nasal irrigation on allergic rhinitis control in children; complementarity between CARAT and MASK outcomes. *Clin Transl Allergy*. 2020;10(1):9. doi:10.1186/s13601-020-00313-2
74. Bhargava C, Verma M, Jakes RW, Okamoto Y. Knowledge and attitude among patients and physicians on allergic rhinitis (KAPPA): an international survey. *J Asthma Allergy*. 2022;15:1645–1664. doi:10.2147/JAA.S382441
75. Glattacker M, Boeker M, Anger R, et al. Evaluation of a mobile phone app for patients with pollen-related allergic rhinitis: prospective longitudinal field study. *JMIR Mhealth Uhealth*. 2020;8(4):e15514. doi:10.2196/15514
76. Ventura MT, Giuliano AFM, Buquicchio R, et al. Implementation of the MASK-Air® App for Rhinitis and Asthma in Older Adults: MASK@Puglia Pilot Study. *Int Arch Allergy Immunol*. 2022;183(1):45–50. doi:10.1159/000518032
77. Park D-Y, Lee YJ, Kim D-K, et al. KAAACI allergic rhinitis guidelines: part 2. update in non-pharmacological management. *Allergy Asthma Immunol Res*. 2023;15(2):145–159. doi:10.4168/aaair.2023.15.2.145
78. Head K, Snidvongs K, Glew S, et al. Saline irrigation for allergic rhinitis. *Cochrane Database Syst Rev*. 2018;6(6):CD012597. doi:10.1002/14651858.CD012597.pub2
79. Li CL, Lin HC, Lin CY, Hsu TF. Effectiveness of hypertonic saline nasal irrigation for alleviating allergic rhinitis in children: a systematic review and meta-analysis. *J Clin Med*. 2019;8(1):64. doi:10.3390/jcm8010064
80. May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. *Clin Ther*. 2017;39(12):2410–2419. doi:10.1016/j.clinthera.2017.10.006

Journal of Asthma and Allergy

Dovepress

Publish your work in this journal

The Journal of Asthma and Allergy is an international, peer-reviewed open-access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-asthma-and-allergy-journal>